Business Standard

Cadila scouts partners to ramp up Covid vaccine production by 50 to 70 mn

The Ahmedabad-based firm is looking to hire contract manufacturers for an additional 50 million to 70 million doses of its plasmid DNA vaccine

Vaccine
Premium

Chris Kay | Bloomberg
Cadila Healthcare Ltd., one of two Indian drugmakers racing to develop an indigenous Covid-19 vaccine, is in talks with potential partners to ramp up production capacity if its candidate passes human clinical trials.

The Ahmedabad-based firm is looking to hire contract manufacturers for an additional 50 million to 70 million doses of its plasmid DNA vaccine, on top of the 100 million that will come from its own capacity, according to Managing Director Sharvil Patel. He declined to name the companies and the amount Cadila has invested in developing the vaccine.

“We’re just waiting for phase II to push that

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 27 2020 | 7:44 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com